Aegis Therapeutics LLC and Australian Drug Discovery company Phylogica Limited today announced a collaboration to use Aegis’ proprietary Intravail® transmucosal delivery formulations to deliver Phylogica’s Phylomer® peptide drugs.
The details can be read here.
No comments:
Post a Comment